GPRC5D has been identified as a promising therapeutic target due to its high expression levels in myeloma cells, in contrast to its minimal expression in normal tissues, with an expression restricted primarily to hair follicles, hard keratinizing tissue (hair shaft, nail, tongue center), and a subset of cells in skin [41]. The gene discussed is GPRC5D; the disease is plasma cell myeloma.